Denise Braendgaard: We are Now the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
Denise Braendgaard, General Manager of Novo Nordisk Haemophilia Foundation, shared a post by Novo Nordisk Haemophilia & Haemoglobinopathies Foundation on LinkedIn:
”The day has finally arrived and I can’t hide my excitement: we are waking up to new horizons.
After years of preparation by our Council and Team – and inspired by our incredible partners – we are immensely proud to announce that we are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation.
It is much more than adding one word.
It represents hope for people affected by haemoglobinopathies – specifically sickle cell disease and thalassaemia – in low and middle income countries who will benefit from our programmes. At the same time, it reaffirms our unwavering commitment to haemophilia.
It is an expansion of our vision and scope, a bold declaration of our continued, long-term dedication after 20 years of Impacting Care. Together.”
Quoting Novo Nordisk Haemophilia & Haemoglobinopathies Foundation’s post:
”We are now the Novo Nordisk Haemophilia & Haemoglobinopathies Foundation
Proudly, we are unveiling our Foundation’s new chapter:
We are expanding our support beyond people with haemophilia to people with sickle cell disease and thalassaemia as well.
Building on two decades of work in haemophilia, and enabled by a renewed partnership with the Novo Nordisk Foundation and the continued funding from our founder, Novo Nordisk, we are expanding our scope to include haemoglobinopathies. We will apply our proven, partnership-led model to develop tailored programmes that benefit people with haemophilia and haemoglobinopathies, their healthcare professionals, and families – always adapted to local needs.
Let us tell you more here.”
Keep up with Hemostasis Today.
-
Jun 11, 2026, 07:41Zia Ullah: Hidden Cerebral Venous Sinus Thrombosis After Dengue Recovery
-
Jun 11, 2026, 07:24Aaron Rodriguez Calienes: RESISTANT Registry Provides Reassuring Safety Data for Acute Intracranial Stenting
-
Jun 11, 2026, 07:17Mbunya. S. Misiani: From the WFH Congress to Meaningful Change for Patients with Bleeding Disorders Worldwide
-
Jun 11, 2026, 07:06Bernard Slater Jr.: Hemophilia B Reminds You that No Matter How Strong You Are, You Are Still Human
-
Jun 11, 2026, 05:11Daniel I McIsaac: Less Blood Loss and No Excess VTE with Tranexamic Acid in High-Risk Surgery
-
Jun 11, 2026, 05:03Aymeric Couturier: Lessons from the TRACK Trial on Anticoagulation in Advanced CKD
-
Jun 11, 2026, 04:53Umut Kocabas: Current Practice and Guideline Adherence on Cancer-Associated Thrombosis in Turkey
-
Jun 11, 2026, 04:40Fernanda Orsi: Which Obstetric APS Patients Are More Likely to Develop Thromboses?
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See